Cancer is the second leading cause of deaths worldwide, with breast cancer being the most frequent in women. Triple-negative breast cancer (TNBC) subtype is the most aggressive type of breast cancer due to the lack of specific therapeutic targets, thus having limited treatment options, low survival prognosis and high recurrence rates. Research groups focusing on the discovery of new drugs to treat cancer are growing. Their focus is related to finding compounds that are more effective and improving the way they are administered, preferentially decreasing side effects and therapeutic resistance. Thus, compounds containing metals have been proposed as antitumor agents and have shown a new perspective for cancer treatment due to their promising therapeutic efficacy. Therefore, this project aims to analyze the mechanisms of uptake of a metallodrug based on copper into TNBC cells in vitro. The copper receptor hCTR1 will be overexpressed through cell transfections with appropriate plasmids and the effects of the copper compound will be tested and compared to non-transfected cells. The results obtained here will help to establish new potential therapeutic targets for TNBC.
News published in Agência FAPESP Newsletter about the scholarship: